Week in Review: 3SBio Acquires Wansheng Pharma for $85 Million

3SBio of Shenyang acquired Zhejiang Wansheng Pharma, a small molecule drugmaker with a compatible portfolio of products, paying $85 million; Ally Bridge Group, a Hong Kong-US investment firm, opened a hedge fund that invests in listed China life science companies; Shenzhen Hepalink Pharma closed its $27 million acquisition of greater China rights to a cardiovascular drug from Canada's Resverlogix; Phagelux, a Shanghai company that is developing phage-based anti-bacterial products, acquired fellow phage company, Utah's OmniLytics; OrbusNeich, headquartered in Hong Kong, enrolled the first patient in a China clinical trial of its COMBO™ Dual Therapy Stent; Eddingpharm of Hong Kong plans to start a China Phase I trial of Brinavess, a drug developed by Cardiome Pharma of Canada to treat atrial fibrillation; Micell Technologies of North Carolina started enrolling patients in a China registrational trial of its drug eluting stent, the MiStent SES®; CASI Pharma, a US-China pharma, reported that Zevalin®, a treatment for non-Hodgkin's lymphoma, is now available in Hong Kong. More details....  Stock Symbols: (HK:1530) (SHE: 002399) (TO: RVX) (NSDQ: CRME) (NSDQ: CASI) Share this with colleagues: // //